Abstract Objective In the Semaglutide Treatment Effect in People with obesity (STEP) trials,
once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body …

Aims Evaluate the effects of once‐weekly subcutaneous semaglutide 2.4 mg on
cardiometabolic risk factors in people with overweight/obesity without diabetes in the STEP …

Objective This study assessed the effects of semaglutide on body weight, cardiometabolic
risk factors, and glycemic status in individuals categorized by baseline BMI with or without …

Background: The 2-year efficacy and safety of once-weekly (OW) subcutaneous semaglutide
2.4 mg vs placebo in adults with overweight/obesity was assessed in the STEP 5 phase 3 …

OBJECTIVE To determine whether semaglutide slows progression of glycemia in people
with cardiovascular disease and overweight or obesity but without diabetes. RESEARCH …

Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether …

People with overweight or obesity often suffer from associated cardiometabolic diseases
and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric …

Aim To explore changes in body weight and cardiometabolic risk factors after treatment
withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) …

The effect of once-weekly sc semaglutide 2.4 mg (sema) on the risk of developing T2D in
people with obesity is unknown. Weight management with sema vs. PBO plus diet/exercise …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …